glp 1 serotonin GLP-1 Drugs and the Physiology of Metabolic Health New research shows GLP-1 medications

36-38 CURRENT GUIDELINE RECOMMENDATIONS: ROLES OF INCRETIN-BASED THERAPIES AND SGLT-2 INHIBITORS The use of currently available treatments for T2DM are guided by clinical recommendations from several organizations, including the ADA and the AACE/ACE

A synthetic version of exendin-4, called exenatide, was approved for medical use by the FDA in 2005

In a study aimed to establish tirzepatde influence on lipid profile [27], at 26 weeks the three dosages of the drug decreased the levels of apoB, apoC-III levels, large triglyceride-rich lipoprotein particles, and small low-density lipoprotein particles compared with both placebo and dulaglutide

doi: 10.1210/clinem/dgae157 124 MoonJSHongJHJungYJFerranniniENauckMALimS

It is important that health professionals and patients get information from official sources and look at clinical studies to know the true risks of this weight management drug

Why dual agonism outperforms single-receptor activation Single GLP-1 agonists like semaglutide produce substantial weight loss, typically 10-15% body weight reduction over 6-12 months